Dublin, May 16, 2018 (GLOBE NEWSWIRE) -- The "Gene Therapy Market (2nd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.
The Gene Therapy Market (2nd Edition), 2018-2030' report provides an extensive study on the current market landscape of gene therapies, with a prime focus on gene augmentation based therapies and oncolytic viral therapies, featuring an elaborate discussion on the future potential of this evolving market.
The year 2017 was particularly eventful; despite the withdrawal of Glybera from the European market in early 2017, the latter half of the year witnessed the approval of two gene therapies, namely Invossa and Luxturna. In fact, Luxturna became the first gene therapy to gain approval in the US. Further, promising clinical results were reported for several gene therapies that are currently in late phases of development.
The growing popularity and potential of gene therapies can be correlated with an exponential increase in the number of patents that have been filed; the cumulative number has increased from 7,300 patents in 2013 to 42,300 patents till the third quarter of 2017. Further, over the past five years, capital worth more than USD 9.8 billion has been invested by venture capital (VC) firms and government bodies to fund research activities in this domain. The overall market is expected to witness significant growth in opportunities for a variety of stakeholders in the coming decade. It is important to highlight that several technology providers, aiming to develop and / or support the development of gene therapies, with improved efficacy and safety, have designed and already introduced advanced platforms for the engineering of vectors. Innovation in this domain has also led to the discovery of novel molecular targets and strengthened the research pipelines of companies focused in this space. The capability to target diverse therapeutic areas is considered to be amongst the most prominent growth drivers of this market.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2018-2030. To account for the uncertainties associated with the development of gene therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution. Key Topics Covered:
1. PREFACE 1.1 Scope of the Report 1.2 Research Methodology 1.3 Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Context and Background 3.2. Evolution of Gene Therapy 3.3. Classification of Gene Therapy 3.4. Routes of Administration 3.5. Mechanism of Action of Gene Therapy 3.6. Advantages and Disadvantages 3.7. Ethical and Social Concerns 3.8. Gene Therapy: Affiliated Methods and Technologies 3.9. Future Constraints and Challenges 3.10. Regulatory Guidelines 4. VIRAL AND NON-VIRAL VECTORS 4.1. Chapter Overview 4.2. Viral Vectors 4.3. Types of Viral Vectors 4.3.1. Adeno-associated Viral Vectors 4.3.2. Adenoviral Vectors 4.3.3. Lentiviral Vectors 4.3.4. Retroviral Vectors 4.3.5. Other Viral Vectors 4.4. Non-Viral Vectors 4.4.1. Types of Non-Viral Vectors 4.4.1.1. Plasmid DNA 4.4.1.2. Liposomes, Lipoplexes and Polyplexes 4.4.1.3. Oligonucleotides 4.4.2. Methods of Transfection 4.4.2.1. Biolistic Methods: Gene Gun 4.4.2.2. Electroporation 4.4.2.3. Receptor Mediated Gene Delivery Methods 4.4.2.4. Gene Activated Matrix (GAM) 4.5. Applications of Viral and Non-Viral Vectors 4.5.1. In Gene Therapy 4.5.2. In Vaccinology 5. COMPETITIVE LANDSCAPE 5.1. Chapter Overview 5.2. Gene Therapy Market: Clinical Pipeline 5.3. Gene Therapy Market: Preclinical / Discovery Pipeline 5.4. Gene Therapy: Key Players 5.5. Gene Therapy: Prominent Hubs 5.6. Gene Therapy: Regional Landscape 6. MARKETED GENE THERAPIES 6.1. Chapter Overview 6.2. Gendicine (Shenzhen SiBiono GeneTech) 6.3. Oncorine (Shanghai Sunway Biotech) 6.4. Rexin-G (Epeius Biotechnologies) 6.5. Neovasculgen (Human Stem Cell Institute) 6.6. Strimvelis (GSK) 6.7. Imlygic (Amgen) 6.8. Invossa (TissueGene) 6.9. Luxturna (Spark Therapeutics) 7. LATE STAGE (PHASE II/III AND ABOVE) GENE THERAPIES 7.1. Chapter Overview 7.2. ASP0113: Overview of Therapy, Key Developments and Clinical Results 7.3. Axalimogene Filolisbac: Overview of Therapy, Key Developments and Clinical Results 7.4. AVXS-101: Overview of Therapy, Key Developments and Clinical Results 7.5. Beperminogene Perplasmid (Collategene): Overview of Therapy, Key Developments and Clinical Results 7.6. Donaperminogene Seltoplasmid (VM202): Overview of Therapy, Key Developments and Clinical Results 7.7. E10A: Overview of Therapy, Key Developments and Clinical Results 7.8. GS-010: Overview of Therapy, Key Developments and Clinical Results 7.9. GSK2696274: Overview of Therapy, Key Developments and Clinical Results 7.10. GSK2696275: Overview of Therapy, Key Developments and Clinical Results 7.11. ImmunoPulse: Overview of Therapy, Key Developments and Clinical Results 7.12. Instiladrin: Overview of Therapy, Key Developments and Clinical Results 7.13. Lenti-D: Overview of Therapy, Key Developments and Clinical Results 7.14. LentiGlobin BB305: Overview of Therapy, Key Developments and Clinical Results 7.15. Ofranergene Obadenovec (VB-111): Overview of Therapy, Key Developments and Clinical Results 7.16. OTL-101: Overview of Therapy, Key Developments and Clinical Results 7.17. Pexastimogene Devacirepvec (Pexa-Vec): Overview of Therapy, Key Developments and Clinical Results 7.18. ProstAtak: Overview of Therapy, Key Developments and Clinical Results 7.19. Valoctocogene roxaparvovec (BMN 270): Overview of Therapy, Key Developments and Clinical Results 7.20. Vigil: Overview of Therapy, Key Developments and Clinical Results 7.21. VGX-3100: Overview of Therapy, Key Developments and Clinical Results 7.22. Vocimagene Amiretrorepvec (Toca-511): Overview of Therapy, Key Developments and Clinical Results 8. EMERGING TECHNOLOGIES 8.1. Chapter Overview 8.2. Genome Editing Technologies 8.2.1. Overview 8.2.2. Applications 8.3. Emerging Technology Platforms 8.3.1. CRISPR / Cas9 System 8.3.2. megaTAL 8.3.3. TALENs 8.3.4. Zinc Finger Nuclease 8.4. Gene Expression Regulation Technologies 8.4.1. RheoSwitch Therapeutic System 8.4.2. Transformative Gene Regulation Technology 8.5. Technology Platforms for Developing / Delivering Gene Therapy 8.5.1. Gene Mediated Cytotoxic Immunotherapy Technology 8.5.2. Innovative Delivery Method 8.5.3. Innovative Modular Technology 8.5.4. In Situ Delivery and Production System (i-DPS) 8.5.5. LentiVector Platform 8.5.6. NAV Technology Platform 9. THERAPEUTICS AREAS 9.1. Chapter Overview 9.2. Cardiovascular Disorders 9.3. Hematological Disorders 9.4. Inflammatory & Infectious Disorders 9.5. Metabolic Disorders 9.6. Muscular Disorders 9.7. Neurological Disorders 9.8. Ocular Disorders 9.9. Oncology 10. FUNDING AND INVESTMENT ANALYSIS 10.1. Chapter Overview 10.2. Types of Funding 10.3. Gene Therapy Market: Funding and Investment Analysis 11. COST PRICE ANALYSIS 11.1. Chapter Overview 11.2. Gene Therapy Market: Factors Contributing to Price Tags 11.3. Gene Therapy Market: Pricing Models 11.3.1. On the Basis of Associated Costs 11.3.2. On the Basis of Competition 11.3.3. On the Basis of Patient Segment 11.3.4. On the Basis of Experts' Opinion 12. PATENT ANALYSIS 12.1. Chapter Overview 12.2. Scope and Methodology 12.3. Gene Therapy Patents: Distribution by Filing Year 12.4. Gene Therapy Patents: Distribution by Geographical Location of Patent Offices 12.5. Gene Therapy Patents: Distribution by CPC Classification 12.6. Gene Therapy Patents: Emerging Areas 12.7. Gene Therapy Patents: Leading Players 12.8. Gene Therapy Patents: Competitive Benchmarking 12.9. Gene Therapy Patents: Valuation Analysis 12.10. Gene Therapy Patents: Leading Citations 13. MARKET SIZING AND OPPORTUNITY ANALYSIS 13.1. Chapter Overview 13.2. Forecast Methodology 13.3. Overall Gene Therapy Market, 2018-2030 13.3.1. Gene Therapy Market: Distribution by Therapeutic Area 13.3.2. Gene Therapy Market: Distribution by Vector Type 13.3.3. Gene Therapy Market: Distribution by Therapy Type 13.3.4. Gene Therapy Market: Distribution by Geography 13.4. Gene Therapy Market: Product-wise Sales Forecasts 13.4.1. Gendicine 13.4.2. Oncorine 13.4.3. Rexin-G 13.4.4. Neovasculgen 13.4.5. Strimvelis 13.4.6. Imlygic 13.4.7. Invossa 13.4.8. Luxturna 13.4.9. ASP0113 13.4.10. Axalimogene Filolisbac 13.4.11. AVXS-101 13.4.12. Beperminogene Perplasmid (Collategene) 13.4.13. Donaperminogene Seltoplasmid (VM202) 13.4.14. E10A 13.4.15. GS-010 13.4.16. GSK2696274 13.4.17. GSK2696275 13.4.18. ImmunoPulse 13.4.19. Instiladrin 13.4.20. Lenti-D 13.4.21. LentiGlobin BB305 13.4.22. Ofranergene Obadenovec (VB-111) 13.4.23. OTL-101 13.4.24. Pexastimogene Devacirepvec (Pexa-Vec) 13.4.25. ProstAtak 13.4.26. Valoctocogene roxaparvovec (BMN 270) 13.4.27. Vigil 13.4.28. VGX-3100 13.4.29. Vocimagene Amiretrorepvec (Toca-511) 14. VIRAL VECTOR MANUFACTURING 14.1. Chapter Overview 14.2. Manufacturing Viral Vectors 14.3. Viral Vector Manufacturing Processes 14.3.1. Mode of Vector Production 14.3.2. Adherent Cells Versus Suspension Cells 14.3.3. Unit Process Versus Multiple Parallel Processes 14.3.4. Cell Culture Systems for Production of Different Viral Vectors 14.4. Serum-Containing Versus Serum-Free Media 14.5. Bioprocessing of Viral Vectors 14.5.1. AAV Vector Production 14.5.2. Adenoviral Vector Production 14.5.3. Lentiviral Vector Production 14.5.4. Retroviral Vector Production 14.6. Challenges Related to Vector Manufacturing 14.7. Companies Offering Contract Services for Viral and Plasmid Vectors 14.8. Partnerships 14.9. Recent Developments 15. CONCLUSION 15.1. Gene Therapy Market is Characterized by a Robust Pipeline of Candidates Being Developed Using Various Types of Vectors 15.2. Although Product Candidates are Being Developed to Treat a Number of Clinical Conditions, the Primary Focus is on Oncology 15.3. Currently, the Market is Led by Big Pharma Players; However, Many Start-ups, Supported by Both Private and Public Investors, are Spearheading Innovation in this Domain 15.4. CMOs are Expected to Continue to Play a Key Role in Driving Manufacturing Efforts in the Industry 15.5. Given the Advancements in Technology Platforms and the Approval of Late Stage Product Candidates, the Market is poised to Grow Significantly in the Foreseen Future 16. INTERVIEW TRANSCRIPTS 16.1. Chapter Overview 16.2. Adam Rogers, CEO, Hemera Biosciences 16.3. Al Hawkins, CEO, Milo Biotechnology 16.4. Cedric Szpirer, Executive & Scientific Director, Delphi Genetics 16.5. Christopher Reinhard, CEO and Chairman, Cardium Therapeutics 16.6. Jeffrey Hung, CCO, Vigene Biosciences 16.7. Marco Schmeer, Project Manager and Tatjana Buchholz, Marketing Manager, PlasmidFactory 16.8. Michael Triplett, CEO, Myonexus Therapeutics 17. APPENDIX 1: TABULATED DATA 18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS Companies Mentioned
- 4BIO Capital
- 5AM Ventures
- Abbott
- Abby Grace Foundation
- Abeona Therapeutics
- Abingworth
- ABL Europe
- Ablynx
- Abraxis BioScience
- Acceleron Pharma
- Acucela (Subsidiary of Kubota Pharmaceutical)
- Adage Capital Management
- Aduro Biotech
- Advanced BioScience Laboratories (ABL)
- Advanced Biotherapeutics Consulting
- Advantagene
- Advaxis Immunotherapies
- Adverum Biotechnologies
- Agent Capital
- Agilis Biotherapeutics
- Ajinomoto Althea
- AJU IB Investment
- Aldevron
- Alexandria Venture Investments
- Allele Biotechnology and Pharmaceuticals
- Ally Bridge Group (ABG)
- Alpha-1 Foundation
- AlphaVax
- Amgen
- AMSBIO
- Anaeropharma Science
- Anemocyte (previously known as Areta International)
- AnGes
- Angionetics
- Apic Bio
- Applied Genetic Technologies Corporation (AGTC)
- Applied Viromics
- ARCH Venture Partners
- Arthrogen
- AstraZeneca
- Athena Vision
- Atlas Venture
- aTyr Pharma
- Audentes Therapeutics
- AveXis
- AVROBIO
- Baillie Gifford
- Bamboo Therapeutics (acquired by Pfizer)
- Batavia Biosciences
- Bayer
- Beckman Research Institute
- Beijing Capital Grand (previously known as Beijing Capital Juda)
- Benitec Biopharma
- BioCanCell Therapeutic
- Biogen
- BioMarin Pharmaceutical
- Biomay
- Biomiga
- BioMotiv
- BioNTech Innovative Manufacturing Services (previously known as EUFETS)
- BioReliance / SAFC
- Bioverativ
- Biovian
- BioViva
- Blue Sky BioServices
- bluebird bio
- BlueWater Angels
- Boehringer Ingelheim BioXcellence
- Boehringer Ingelheim Venture Fund
- Bpifrance
- Brammer Bio
- Bristol-Myers Squibb
- Broad Institute
- Brookside Capital Partners Fund
- California Institute for Regenerative Medicine (CIRM)
- Cambridge Enterprise
- Cancer Prevention and Research Institute of Texas (CPRIT)
- CapDecisif Management
- Caribou Biosciences
- Casdin Capital
- Celgene
- Cell and Gene Therapy Catapult
- Cellectis
- CellGenTech
- Celsion
- Center for the Development of Industrial Technology (CDTI)
- Centre for Process Innovation
- Centre national de la recherche scientifique (CNRS)
- CEVEC Pharmaceuticals
- CHDI Foundation
- Chiesi Farmaceutici
- Children's Medical Research Foundation
- Children's Hospital of Philadelphia
- Children's Medical Research Foundation
- Clarus Ventures
- Clough Capital Partners
- Cobra Biologics and Pharmaceutical Services
- Cold Genesys
- Columbus Venture Partners
- Commercial & External Partnership, Industrial Affairs (CEPiA)
- Copernicus Therapeutics
- Cormorant Asset Management
- Cowen
- Creative Biogene
- CRISPR Therapeutics
- Cure Sanfilippo Foundation
- CureVac
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Deerfield Management Company
- Dimension Therapeutics (acquired by Ultragenyx Pharmaceutical)
- DNAtrix Therapeutics
- Easton Capital
- EcoR1 Capital
- Editas Medicine
- Elk OrthoBiologics
- Emergent BioSolutions
- Eminent Venture Capital
- enGenes
- Ensysce Biosciences
- Epeius Biotechnologies
- Errant Gene Therapeutics
- Esteve
- Etubics
- Eurofins Genomics
- Eurogentec
- European Investment Bank (EIB)
- Expression Therapeutics
- ExSight Capital
- Eyevensys
- Federal Holding and Investment Company (SFPI-FPIM)
- Fibrocell Science
- Fireman Capital Partners
- FKD Therapies
- Flagship Pioneering (previously known as Flagship Ventures)
- Fondacin Genoma Espaa
- Fondation Sanfilippo Suisse
- Fondazione Telethon and Ospedale San Raffaele
- Forbion Capital Partners
- Foresite Capital Management
- FoxKiser
- F-Prime Capital Partners (previously known as Fidelity Biosciences)
- Franklin Advisers
- Franklin Templeton Investments
- Fred Hutchinson Cancer Research Center
- Freeline Therapeutics
- Friedreich's Ataxia Research Alliance (FARA)
- FUJIFILM Diosynth Biotechnologies
- Fund+
- Fundacin Sanfilippo B
- Fundacin Stop Sanfilippo
- Further Lane Securities
- Gene Medicine Japan (GMJ) / Kobe Biomedical Accelerator
- GeneCure Biotechnologies
- GeneDetect
- GeneImmune Biotechnology
- Genelux
- Genentech
- GeneOne Life Science
- Genethon
- Genexine
- GenIbet Biopharmaceuticals
- Genprex
- GenScript Biotech
- GenSight Biologics
- GenVec
- GlaxoSmithKline
- Global BioTherapeutics
- GlobeImmune
- GO Capital Amorage
- Google Ventures (GV)
- Gradalis
- Green Cross Holdings
- Guangzhou Double Bio-products
- Harvard University
- HealthCap
- Hemera Biosciences
- Herantis Pharma
- Hercules Capital
- Hoffmann-La Roche
- HORAMA
- Horizon Discovery
- Horizon Pharma
- Huapont Life Sciences
- Human Stem Cells Institute
- I2BF Global Ventures
- Ichor Therapeutics
- Ichor Systems
- ID Pharma
- Idinvest Partners
- Immune Technology
- Imperial Innovations
- Inception Capital Management
- Index Ventures
- Innovation Network Corporation of Japan (INCJ)
- Innovative Genomics Institute (IGI)
- Inovio Pharmaceuticals
- Inserm
- Intellia Therapeutics
- Intrexon
- Invesco Perpetual
- InvivoGen
- Ion Channel Innovations
- Iowa State University
- Israel Innovation Authority
- Janssen
- Janus Capital Management
- Jennison Associates
- Johns Hopkins University
- Johnson & Johnson Development Corporation
- JumpStart Ventures
- Juventas Therapeutics
- Kaneka Eurogentec
- Khosla Ventures
- Kiwoom Securities
- Knight Therapeutics
- KOLON LIFE SCIENCE
- Krystal Group
- Kubota Pharmaceutical
- Kurma Partners
- Leerink Transformation Partners
- Leland Stanford Junior University
- Lentigen Technology (wholly owned subsidiary of Miltenyi Biotec)
- Leukon Investments
- Lime Asset Management
- Lonza
- Louisiana State University (LSU)
- Luminous BioSciences
- Lundbeckfonden Ventures
- Lysogene
- Marsala Biotech
- Maryland Technology Development Corporation (TEDCO)
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- MassBiologics
- Medarex
- Medigen Biotechnology
- MedImmune
- Medtronic
- MeiraGTx
- Mercia Technologies
- Merck
- Mercury Fund
- Meridian Life Science
- MERITZ Securities
- MidCap Financial
- Milo Biotechnology
- Miltenyi Biotec
- Mita Securities
- Mitsubishi Tanabe Pharma
- Mitsubishi UFJ Capital
- Moderna Therapeutics
- Molecular Diagnostic Services(MDS)
- MolMed
- MOLOGEN
- Momotaro-Gene
- Morningside Group
- Movember Foundation
- Myonexus Therapeutics
- NanoCor Therapeutics
- NanoDimension Venture Firm
- NantCell
- Nantes Gene Therapy Institute
- National Cancer Institute (NCI)
- National Eye Institute (NEI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute on Drug Abuse (NIDA)
- National Institutes of Health (NIH)
- National MPS Society
- National Securities Corporation (NSC)
- Nature Technology
- Neuralgene
- Neurotech Pharmaceuticals
- New Energy and Industrial Technology Development Organization (NEDO)
- New Enterprise Associates (NEA)
- New Leaf Venture Partners
- New River Management
- NewVa Capital Partners
- Nightstar Therapeutics
- Nohla therapeutics
- Novartis
- Novartis Venture Fund
- Novasep
- Novo Seeds
- Oberland Capital
- Okairos
- Omega Fund Management
- Omnes Capital
- Omnia Biologics
- Oncolys BioPharma
- OncoSec Medical
- OrbiMed Advisors
- ORCA Therapeutics
- Orchard Therapeutics
- ORI Capital
- Osage University Partners
- Oxford BioMedica
- Oxford Finance
- Oxford Genetics
- PacificGMP (a part of Abzena Group)
- Pangu BioPharma
- Panmure Gordon
- Paragon Bioservices
- Partners Innovation Fund
- Pavilion Capital Partners
- PeriphaGen
- Pfizer
- PhaseRx
- PlasmidFactory
- PNP Therapeutics
- Polaris Partners
- Pontifax
- Posco Capital Partners
- Poseida Therapeutics
- Precision BioSciences
- Profectus BioSciences
- Promethera Biosciences
- PsiOxus Therapeutics
- Puresyn
- Quethera
- RA Capital Management
- RBV Capital
- Red Sanfilippo Foundation
- Redmile Group
- Regeneron Pharmaceuticals
- REGENXBIO
- Relieve Genetics
- Renova Therapeutics
- RetroSense Therapeutics (acquired by Allergan)
- Rev1 Ventures (previously known as TechColumbus)
- REYON Pharmaceutical
- Richter-Helm BioLogics
- Ridgeback Capital Management
- Roche
- Roche Venture Fund
- Rock Springs Capital Management
- Rocket Pharma
- RTW Investments
- Rusnano
- SAB Technology
- Sabby Capital
- San Raffaele Telethon Institute for Gene Therapy (SR-TIGET)
- SanBio
- Sanfilippo Children's Foundation
- Sanfilippo Children's Research Foundation (SCRF)
- Sanfilippo Research Foundation (SRF)
- Sangamo Therapeutics
- Sanofi
- Sanofi Genzyme
- Sanofi-Genzyme BioVentures
- Santen Pharmaceutical
- Sarepta Therapeutics
- Scancell
- Sectoral Asset Management
- Selecta Biosciences
- Seventure Partners' Health for Life Capital fund
- Sham Innovation Sant
- Shanghai Sunway Biotech
- Shenzhen Qianhai Taxus Industry Capital Management
- Shenzhen Sibiono GeneTech
- Shinhan Capital
- Shinsei Corporate Investment
- Shire
- Sigma-Aldrich (now a part of Merck)
- SignaGen Laboratories
- Sino Biological
- SIRION Biotech
- Skolkovo Foundation
- SMS Investments
- Sofinnova Ventures
- Song Hong Fang
- Spark Therapeutics
- Sphera Global Health Care
- SR One (investment arm of GlaxoSmithKline)
- Stratophase
- StrideBio
- SV Life Sciences Investors
- Syncona Partners (a subsidiary of the Wellcome Trust)
- Synpromics
- Synthace
- System Biosciences
- T. Rowe Price
- Takeda Pharmaceutical
- Target ALS Foundation
- Targeted Technology Fund
- Targovax
- Team Sanfilippo
- Tekes
- Temasek Holdings
- Tethys Ventures
- The Finnish Funding Agency for Technology and Innovation
- The French Muscular Dystrophy Association (AFM-Tlthon)
- The Jagen Group
- The Scripps Research Institute
- TheraBiologics
- TheraVectys
- Thermo Fisher Scientific
- Third Rock Ventures
- Third Security
- TissueGene
- Tocagen
- Transgene
- Tufts Financial Group (TFG)
- Turenne Sant
- TVM Capital
- Two Blades Foundation
- UB Securities
- UCL Technology Fund
- UK Innovation & Science Seed Fund (UKI2S, previously known as The Rainbow Seed Fund)
- uniQure
- University of California
- University of Florida
- University of Minnesota
- University of Pennsylvania
- University of Texas
- University of Washington
- Valneva
- Vascular Biologics (also known as VBL Therapeutics)
- VCN Biosciences
- Vectalys
- Vector Biolabs
- Vecura (Karolinska University Hospital)
- Venrock
- Versant Ventures
- Vertex Pharmaceuticals
- VESSL (previously known as MultiGene Vascular Systems )
- Vibalogics
- Vical
- Vigene Biosciences
- Viking Global Investors
- Virginia Biosciences Health Research Corporation (VBHRC)
- ViroMed
- Virovek
- Virttu Biologics (acquired by Sorrento Therapeutics)
- VIVEbiotech
- Vivet Therapeutics
- Vivo Capital
- Voyager Therapeutics
- Waisman Biomanufacturing
- Wellcome Trust
- Wellington Management Company
- Wellstat Ophthalmics
- Whitesun Healthcare Ventures
- WI Harper Group
- Woodford Investment Management
- WuXi AppTec
- XyloCor Therapeutics
- Ysios Capital
- Yuhan
- ZIOPHARM Oncology
For more information about this report visit https://www.researchandmarkets.com/research/c...erapy?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Genomics
